Teva Told to Pay Glaxo $235.5 Million for Infringing Patent

A federal jury June 20 awarded GlaxoSmithKline $234.11 million in lost profits and $1.4 million in royalties for Teva’s infringement of a patent for Coreg, a beta-blocker used to treat congestive heart failure (GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., D. Del., 14-cv-00878, jury verdict 6/20/17).

The verdict, handed down June 20 in the U.S. District Court for the District of Delaware, is particularly noteworthy because juries normally don’t decide pharmaceutical patent litigation matters in Hatch-Waxman Act cases.

“That a jury decided liability and damages in this very complex case is noteworthy, and I expect that the ...